Sidley represented Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, in its completion of an oversubscribed Series E financing round, which raised US$120 million to accelerate the company’s mission of transforming the percutaneous ventricular assist device (pVAD) market. Funds from the round will go towards expanding Supira’s clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS).
The round was led by new investors Novo Holdings and Qatar Investment Authority, along with participation from two strategic investors. Existing investors, including Cormorant Asset Management, The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures also participated in the financing.
For additional information, please refer to the press release.
The Sidley team was led by Frank Rahmani (Capital Markets, Emerging Companies and Venture Capital), and included Nick DeAngelis, Jake Funk, and Samantha Carvalho (M&A and Private Equity); Stephen Abreu and Longbo Wang (Technology and Life Sciences); Idan Netser (Emerging Companies and Venture Capital); and Rebecca Stuart (Labor and Employment).
